Cardiovascular Systems, Inc. (CSII)
(Delayed Data from NSDQ)
$39.49 USD
+1.98 (5.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.49 USD
+1.98 (5.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cardiovascular Systems (CSII) Introduces Diamondback in Canada
by Zacks Equity Research
The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.
Cardiovascular Systems (CSII) Q4 Loss Narrower Than Expected
by Zacks Equity Research
Strength in both coronary and peripheral segments drove Cardiovascular Systems' (CSII) revenues in the fiscal fourth quarter.
Cardiovascular Systems (CSII) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 17.65% and 2.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cardiovascular Systems (CSII) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips
by Zacks Equity Research
Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.
Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable
by Zacks Equity Research
Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.
Cardiovascular Systems (CSII) Q3 Loss Widens, Gross Margin Dips
by Zacks Equity Research
Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.
Cardiovascular Systems (CSII) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -50.00% and -0.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) Inks Deal to Enhance Patient Care
by Zacks Equity Research
Cardiovascular Systems' (CSII) investment in CarePICS will advance patient access to the suitable treatment at the right time, thereby leading to improved care and reduced amputations.
5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic
by Debanjana Dey
Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.
Cardiovascular Systems' (CSII) New Buyout Boosts CAD/PAD Line
by Zacks Equity Research
Cardiovascular Systems' (CSII) acquisition of Peripheral Support Catheters will enhance outcomes for patients undergoing complex peripheral and coronary interventions.
Cardiovascular Systems' (CSII) WIRION Cures 1st U.S Patient
by Zacks Equity Research
Cardiovascular Systems' (CSII) WIRION demonstrated a major adverse event rate of 1.9%, which is lower than the earlier reported rates for other lower extremity embolic protection filters.
Cardiovascular Systems (CSII) Down 2.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe
by Zacks Equity Research
Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.
Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2
by Zacks Equity Research
Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.
Cardiovascular Systems (CSII) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 100.00% and -1.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
4 MedTech Underperformers Poised for a Turnaround in 2021
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
Cardiovascular Systems' (CSII) OAS Gets CE Mark for Use in Europe
by Zacks Equity Research
Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.
5 MedTech Stocks That Have Outperformed the Industry in 2020
by Debanjana Dey
Here are a few MedTech stocks which continued to outperform their respective industries amid the pandemic and can turn out to be wise investment choices.
3 MedTech Growth Stocks With Solid Prospects for 2021
by Zacks Equity Research
Here are a few MedTech growth stocks poised for a rebound that investors can scoop up to reap profits going into 2021.
Why Is Cardiovascular Systems (CSII) Down 4.4% Since Last Earnings Report?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 MedTech Stocks Gaining Ground on COVID-19 Test Kit Success
by Debanjana Dey
Here are a few coronavirus-testing MedTech stocks that investors can scoop up to reap profits amid the pandemic-battered stock market situation.
Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.
Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 78.26% and 7.59%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cardiovascular Systems (CSII) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.